# US 2021/0330778 A1 · Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330778 A1
- Document ID: US20210330778A1
- Status: Published application
- Kind: A1
- Application number: 17/369,230
- Filed: 2021-07-07
- Published: 2021-10-28
- Earliest claimed: 2017-02-24
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Jian He; John E. MacNair; William J. Smith; Michael A. Winters; Joseph G. Joyce; Chitrananda Abeygunawardana; Luwy Musey; Hari Pujar
- Web page: https://patentgrep.com/patent/US20210330778A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 39/116: Polyvalent bacterial antigens
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 31/04: Antibacterial agents
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

## Claims

### Claim at position 1

1-44. (canceled)

### Claim 45

A method of preparing a pneumococcal polysaccharide-protein conjugate by reductive amination, the method comprising:
a) reacting a Streptococcus pneumoniae polysaccharide selected from serotypes 3, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F with an amount of an oxidant to form an activated polysaccharide having an activation level from 0.05 to 0.22; and
b) reacting the activated polysaccharide with a carrier protein in an aprotic solvent to form a polysaccharide-protein conjugate;
wherein the resulting polysachharide-protein conjugate has a lysine loss value between 7.0 and 18.0 inclusive.

### Claim 46 (depends on 45)

The method of claim 45, wherein the activation level is from 0.09 to 0.22.

### Claim 47 (depends on 45)

The method of claim 45, wherein the reacting in step b) is in the presence of a reducing agent.

### Claim 48 (depends on 45)

The method of claim 45, wherein the carrier protein is selected from the group consisting of tetanus toxoid, diphtheria toxoid, and CRM197.

### Claim 49 (depends on 48)

The method of claim 48, wherein the carrier protein is CRM197.

### Claim at position 7

50-53. (canceled)
